Annals of Oncology Advance Access published online on October 16, 2006
Annals of Oncology, doi:10.1093/annonc/mdl351
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Senior Medical Advisor
* To whom correspondence should be addressed.
letter to the editor
The cost-effectiveness of bisphosphonates in metastatic breast cancer: letter to the editor in response to Botteman et al. 2006
B. Souberbielle 1 *, R. Williams 2, and E. McCloskey 3
2 Medical Information Officer, Schering Health Care Ltd, The Brow, Burgess Hill, West Sussex RHI5 9NE
3 WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX
B. Souberbielle, E-mail: bsouberbielle{at}schering.co.uk
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann. Onc., March 1, 2008; 19(3): 420 - 432. [Abstract] [Full Text] [PDF] |
||||
